---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-387351"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2026-09-10T12:48:26+00:00"
generated_at: "2026-09-10T12:50:07.027307+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# DISC-3405 cuts phlebotomy events 85% in PV Phase 2; hematocrit controlled <45%

## Summary
- Mean phlebotomy events fell from 4.0 to 0.6 per 26 weeks (p<0.0001) in Cohort A (n=13).
- 61.5% of patients phlebotomy-free through 26 weeks; 77.8% during maintenance (weeks 12-32, n=9).
- Hematocrit maintained <45% through week 26 with improved symptom burden; dose-proportional PK, increased hepcidin.
- DISC-3405 well-tolerated; mild injection site reactions; adverse events consistent with underlying disease.
- Company plans RESTORE-PV update and sickle cell data by end of 2026; selcodebart FDA feedback expected.

## SEC filing metadata
- accession: 0001193125-26-387351
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2026-09-10T12:48:26+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312526387351/0001193125-26-387351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312526387351/iron-20260909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-387351
- JSON: https://secwatch.observer/filing/0001193125-26-387351.json
- Plain text: https://secwatch.observer/filing/0001193125-26-387351.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.